Senhwa Biosci 
Welcome,         Profile    Billing    Logout  
 1 Product   4 Diseases  1 Product   3 Trials   95 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pidnarulex (CX-5461) / Senhwa Biosci
ACTRN12613001061729: A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies

Terminated
1
40
 
Peter MacCallum Cancer Centre, National Health and Medical Research Council
Any advanced Haematologic Malignancy
 
 
CX-5461-04, NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Recruiting
1
52
Canada, US
CX-5461, Pidnarulex
Senhwa Biosciences, Inc.
Advanced Solid Tumor
12/24
06/25
REPAIR, NCT05425862: Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Suspended
1
48
RoW
Pidnarulex, CX-5461, Talazoparib
Peter MacCallum Cancer Centre, Australia
Metastatic Castration Resistant Prostate Cancer (mCRPC)
07/24
12/25
NCT06606990: Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Not yet recruiting
1
40
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pidnarulex, CX-5461, CX5461, Pol I Inhibitor CX5461, RNA Pol I Inhibitor CX5461
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm
03/27
03/27
silmitasertib (CX-4945) / Senhwa Biosci
NCT06202521: CX-4945 in Viral Community Acquired Pneumonia

Recruiting
2
136
RoW
CX-4945 (SARS-CoV-2 domain), Silmitasertib, Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain), Placebo (Influenza virus domain)
Senhwa Biosciences, Inc.
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza with Pneumonia
03/25
06/25
NCT06541262: Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Recruiting
1/2
114
US
Silmitasertib, CX-4945, Irinotecan, Temozolomide, Vincristine
Milton S. Hershey Medical Center
Neuroblastoma Recurrent, Ewing's Sarcoma Recurrent, Osteosarcoma Recurrent, Rhabdomyosarcoma Recurrent, Liposarcoma Recurrent
11/30
11/35
NCT03904862: Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Suspended
1/2
60
US
CX 4945, Silmitasertib sodium
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI), American Lebanese Syrian Associated Charities (ALSAC)
Medulloblastoma, Childhood
12/28
02/29
NCT05817708: A Study of Silmitasertib (CX-4945) in Healthy Subject

Completed
1
30
RoW
CX-4945, Silmitasertib
Senhwa Biosciences, Inc.
COVID-19
03/23
06/23
NCT03897036: Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Active, not recruiting
1
25
US
CX-4945
Senhwa Biosciences, Inc.
Carcinoma, Basal Cell
09/23
12/23

Download Options